PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Sees Large Increase in Short Interest

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the target of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 5,259 shares, a growth of 36.2% from the January 29th total of 3,860 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,887 shares, the short-interest ratio is presently 2.8 days. Based on an average daily trading volume, of 1,887 shares, the short-interest ratio is presently 2.8 days. Approximately 0.0% of the company’s shares are sold short.

Institutional Trading of PureTech Health

Several institutional investors have recently made changes to their positions in PRTC. Persistent Asset Partners Ltd acquired a new stake in shares of PureTech Health during the 2nd quarter worth $29,000. Diadema Partners LP purchased a new stake in PureTech Health during the second quarter valued at about $126,000. Lansdowne Partners UK LLP acquired a new stake in PureTech Health during the third quarter worth about $260,973,000. Finally, Pentwater Capital Management LP increased its stake in PureTech Health by 50.0% during the third quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock worth $1,388,000 after acquiring an additional 25,000 shares during the last quarter. 0.04% of the stock is owned by hedge funds and other institutional investors.

PureTech Health Price Performance

Shares of PRTC traded up $0.73 during mid-day trading on Monday, hitting $17.50. The company had a trading volume of 9,506 shares, compared to its average volume of 3,671. PureTech Health has a 1-year low of $13.30 and a 1-year high of $20.00. The business’s 50-day simple moving average is $17.93 and its 200-day simple moving average is $17.46.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of PureTech Health in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

PureTech Health Company Profile

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.